Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL5809985 | 1.00 | — | — | |
| Water SCHEMBL11750618 | 1.00 | CA2 (0.54) | — | |
| Water SCHEMBL1697235 | 1.00 | CA2 (0.54) | — | |
| Water SCHEMBL9333419 | 1.00 | — | — | |
| Water SCHEMBL7032487 | 1.00 | CA2 (0.54) | — | |
| Water SCHEMBL1120078 | 1.00 | — | — | |
| Water SCHEMBL8140555 | 1.00 | CA2 (0.54) | — | |
| Water SCHEMBL22581621 | 0.95 | — | — | |
| Water SCHEMBL22581609 | 0.95 | — | — | |
| Water SCHEMBL10342957 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 828 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599606-B2 | Therapies with 3rd generation EGFR tyrosine kinase inhibitors | JANSSEN BIOTECH, INC. (US) | 2026-04-14 | — | — | US | claimed |
| EP-4716538-A1 | METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) | Janssen Biotech, Inc. (US) | 2026-04-01 | — | — | EP | claimed |
| WO-2026042017-A1 | AMIVANTAMAB IN COMBINATION WITH LAZERTINIB FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) | JANSSEN BIOTECH, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| WO-2026041980-A1 | METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) | JANSSEN BIOTECH, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| US-12558345-B2 | CHK1/2 inhibitors for use in the treatment of neuroblastomas and/or soft tissue sarcomas | ELI LILLY AND COMPANY (US) | 2026-02-24 | — | — | US | claimed |
| US-20260048065-A1 | METHODS FOR TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) | JANSSEN BIOTECH INC (US) | 2026-02-19 | — | — | US | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| WO-2025052273-A1 | METHODS OF TREATING NON-SMALL CELL LUNG CANCER | JANSSEN BIOTECH, INC. (US) | 2025-03-13 | — | — | WO | claimed |
| CN-119497614-A | Compositions and formulations for preventing, treating and ameliorating skin diseases, conditions and disorders using PK inhibitors | 德慕拜昂生物科技公司 | 2025-02-21 | — | — | CN | claimed |
| US-12227510-B2 | Crystal form of acid addition salt of furopyrimidine compound | HANMI PHARM. CO., LTD. (KR) | 2025-02-18 | — | — | US | claimed |
| US-20050124631-A1 | Inhibitors of polyq-aggregation | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2005-06-09 | — | — | US | claimed |
| EP-1416931-A1 | INHIBITORS OF POLYQ-AGGREGATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2004-05-12 | — | — | EP | claimed |
| WO-2003015772-A1 | INHIBITORS OF POLYQ-AGGREGATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2003-02-27 | — | — | WO | claimed |
| CN-1384829-A | sodium-hydrogen exchanger type 1 inhibitor crystal | PFIZER PROD INC (US) | 2002-12-11 | — | — | CN | claimed |
| CN-1093759-C | Protein kinase C inhibitors | LILLY CO ELI (US) | 2002-11-06 | — | — | CN | claimed |
| CN-1223261-A | Novel 2-thiocarbpenems | AMERICAN CYANAMID CO (US) | 1999-07-21 | — | — | CN | claimed |
| WO-1997033580-A1 | MAINTAINING KIDNEY FUNCTION DURING SURGERY OR TRAUMA | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 1997-09-18 | — | — | WO | claimed |
| WO-1997018809-A1 | PROTEIN KINASE C INHIBITOR | ELI LILLY AND COMPANY (US) | 1997-05-29 | — | — | WO | claimed |
| CN-1104214-A | Novel 2-thiocarbpenems | AMERICAN CRANAMID COMPANY (US) | 1995-06-28 | — | — | CN | claimed |
| CN-1047494-A | 2-amino-1,2,3,4-tetralin compounds that new 8-replaces | ASTRA AB (SE) | 1990-12-05 | — | — | CN | claimed |